By AACR Associate Member Council members, 2025-2026 Attending the AACR Annual Meeting is a defining moment for early‑career researchers...
The rapid fire of U.S. Food and Drug Administration (FDA) approvals of new anticancer therapeutics continued last week when...
Breast cancer researchers are packed up in San Antonio, eager to build on the latest information they gathered at...
Breast cancer recurrence rates were similar for postmenopausal women with estrogen receptor-positive DCIS whether they took anastrozole or tamoxifen,...
T-DM1, a HER2-targeted antibody-drug conjugate, improved outcomes for patients with HER2-positive, metastatic breast cancer that had progressed despite prior...
Breast-conserving surgery may be a better option than mastectomy for patients with early-stage breast cancer.
Adding denosumab (Xgeva) to adjuvant aromatase inhibitor therapy improved disease-free survival for postmenopausal women with early-stage hormone receptor-positive breast...
Studies presented at this year’s San Antonio Breast Cancer Symposium shed light on new investigational therapies for patients with...
Guest Post by Kent Osborne, MD Director of the Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine;...
On Monday, the U.S. Food and Drug Administration (FDA) rounded out an exciting month for the multiple myeloma community...
As lung cancer awareness month drew to a close, the U.S. Food and Drug Administration (FDA) added another therapeutic...